Campbell, Jonathan E.
Drucker, Daniel J.
Article History
First Online: 7 April 2015
Competing interests
: D.J.D. has served as a consultant for companies developing incretin-based therapies for the treatment of diabetes mellitus, including Arisaph Pharmaceuticals, Intarcia Therapeutics, MedImmune, Merck Research Laboratories, Novo Nordisk, NPS Pharmaceuticals and Receptos. Neither D.J.D. nor his family members hold stock directly or indirectly in any of these companies. Preclinical studies in D.J.D.'s laboratory are supported, in part, by grants to Mount Sinai Hospital from Merck, Novo Nordisk and Sanofi. J.E.C. declares no competing interests.